Compounds that reactivate mutant p53

By developing compounds and compositions with specific structures, the problem of the inability to effectively target multiple TP53-mutant cancers in existing technologies has been solved, achieving the restoration of p53 activity and demonstrating therapeutic and preventative effects against Li-Fraumeni syndrome.

CN122228090APending Publication Date: 2026-06-16INST FOR CANCER RES D B A THE RES INSTITUE OF FOX CHASE CANCER CENT
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
INST FOR CANCER RES D B A THE RES INSTITUE OF FOX CHASE CANCER CENT
Filing Date
2024-05-22
Publication Date
2026-06-16

AI Technical Summary

Technical Problem

Existing compounds that restore p53 activity have limitations and cannot effectively target a variety of TP53-mutant cancers, especially lacking broad applicability in Li-Fraumeni syndrome (LFS).

Method used

A new class of compounds and compositions have been developed that can restore the activity of mutant p53 by binding to it through specific structures. These include compounds and pharmaceutical compositions with specific structures that can be used to restore the function of p53 upon contact with cells or subjects.

Benefits of technology

These compounds and compositions can selectively restore p53 activity in a variety of TP53-mutant cancers, with potential therapeutic and preventative effects, particularly in Li-Fraumeni syndrome, where they significantly reduce cancer risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122228090A_ABST
    Figure CN122228090A_ABST
Patent Text Reader

Abstract

The present disclosure relates to compounds that restore p53 activity and methods of using the compounds to treat various disorders associated with loss of p53 activity, such as cancer, e.g., sarcoma, carcinoma, head and neck cancer, hematological cancer, solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disease, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung cancer, small cell lung cancer, kidney cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to limit the present application.
Need to check novelty before this filing date? Find Prior Art